Prohost Biotech
Contributor since: 2009
Company: Prohost Biotech
Latest Articles
BioMarin Decision Might Add More Stress Than Put Pressure On The FDA To Approve Sarepta Drug
Why Switzerland Approval Of Exelixis And Roche Drug Combination For Melanoma Is A Big Deal
ImmunoGen: Defeating Advanced Ovarian Cancer And Other Malignancies
Vertex: The FDA Advisory Committee Recommended Approval For Orkambi
Aerie Pharmaceuticals Is Speeding Towards Improving The Management Of Glaucoma
Has The Time Come To Appreciate Agenus?
Tokai: A Newcomer To The Biotechnology Market
Gilead's Sovaldi Is The Solution, Not The Problem
Prosensa: Back Into The Limelight
Incyte Shows Its Path Towards Growth
Halozyme: Financing PEGPH20 Is Worth Raising Money
Intercept Liver Drug Is A Game Changer For The Biotech Industry
Arca Biopharma: A Genetically Targeted Drug For Atrial Fibrillation In Heart Failure Patients
Why Amgen Is Still The King
Gilead Sciences: A Unique Stallion
Sequenom: Current Status
Geron's Promising News Poses No Threat To Incyte
ImmunoGen: Opinions Are Being Expressed. Here Is Our View
The Time Has Come For Valuing ImmunoGen Technology And Pipeline Products
Could Agenus Vaccine For Glioblastoma Be Assigned Breakthrough Designation?
Agenus Offers An Investment Opportunity
Yes, Gilead Did It Again
Ariad: Succumbing Temporarily To Extraordinary Pressure
Regeneron's Horse Eylea Triples Its Speed
3 Small Biotech Firms In The Spotlight
Illumina And The Future Of Life Sciences
A Great Day And A Great Future For Alnylam
Unreasonable Cause For Selling Cytokinetics
Onyx Takeover Was Expected
2 Small, Great Biotechs Underestimated By The Market
Why The Amgen And Cytokinetics Agreement Is Good News
The True Value Of Seattle Genetics